Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers.

ABSTRACT:

Importance

Accurate risk prediction models using routinely measured biomarkers-eg, carbohydrate antigen 19-9 (CA19-9) and bilirubin serum levels-for pancreatic cancer could facilitate early detection of pancreatic cancer and prevent potentially unnecessary diagnostic tests for patients at low risk. An externally validated model using CA19-9 and bilirubin serum levels in a larger cohort of patients with pancreatic cancer or benign periampullary diseases is needed.

Objective

To assess the discrimination, calibration, and clinical utility of a prediction model using readily available blood biomarkers (carbohydrate antigen 19-9 [CA19-9] and bilirubin) to distinguish early-stage pancreatic cancer from benign periampullary diseases.

Design, setting, and participants

This di

SUBMITTER: Boyd LNC 

PROVIDER: S-EPMC10463099 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature